Kjell Norling joins the board of Rhenman & Partners
Kjell Norling, former CEO of PP Pension, has been appointed to the board of Rhenman & Partners. Kjell brings extensive experience from the financial sector, having held several senior roles in asset management. Additionally, he possesses significant expertise in distribution-related matters. Kjell has previously been Director at KPMG, Head of Global Fund Distribution at SEB […]
Kjell Norling ny ledamot i Rhenman & Partners styrelse
Kjell Norling, tidigare VD för PP Pension, ansluter till Rhenman & Partners styrelse. Kjell har en lång och bred bakgrund inom finanssektorn med erfarenhet av asset management i ledande positioner. Kjell har dessutom en gedigen erfarenhet av distributionsfrågor. Bland tidigare roller återfinns Director vid KPMG, Head of Global Fund Distribution hos SEB Asset Management […]
Rhenman & Partners reflektion: Hälsovårdssektorn 2025 och framåt
2025 var ett år präglat av två tydliga halvor för hälsovårdssektorn. Under första halvåret låg fokus på politisk osäkerhet och svag finansieringsmiljö inom bioteknik. Under andra halvåret minskade den politiska osäkerheten samtidigt som finansieringsmiljön förbättrades. Därmed flyttades marknadens uppmärksamhet till de starka fundamenta som präglar sektorn. Rhenman Healthcare Equity L/S avslutade 2025 med en positiv […]
Healthcare sector 2025 review and outlook
2025 was a year defined by two distinct narratives for the healthcare sector. During the first half of the year, attention was heavily focused on political uncertainty and weak biotech funding. In contrast, the second half of the year saw decreased political uncertainty and a better funding environment. With the market shifting focus to the […]
Two halves, two stories – the healthcare sector 2025 annual recap
2025 has been a year defined by two distinct narratives for the healthcare sector. During the first half of the year, attention was heavily focused on political uncertainty and the presence of unknown factors. In contrast, the second half of the year has seen a shift in focus toward established Most Favored Nation (MFN) deals […]
Monthly comment (November 2025): Continued momentum for the healthcare sector
The healthcare sector had continued momentum in November, with focus shifting from political uncertainty to underlying fundamentals. Another strong month for the fund which saw positive contributions from all sub-sectors, with biotechnology making the strongest contribution. The fund benefited from the acquisition of Exact Sciences by Abbott. While the outlook for the sector overall looks […]
Investeringschef Henrik Rhenman gästar Direkt med Förvaltarna
Rhenman & Partners investeringschef Henrik Rhenman deltar i Direkt med förvaltarna där han samtalar med programledare Eric Lindeen om läget i hälsovårdssektorn och om fonden. Eric och Henrik diskuterar bland annat innovationen och tillväxten i sektorn, Henrik delar dessutom sin syn på vikten av små- och medelstora bolag i fonden. Hela avsnittet går att […]
Monthly comment (October 2025): Earnings season off to a strong start
Summary Strong start to the earnings season for the healthcare sector, supported by further Most Favored Nation deals, and continued positive momentum in biotechnology. The fund delivered strong results with positive contributions from all subsectors, led by biotechnology and medical technology. Exposure to biotechnology was increased, financed by reduced exposure to pharmaceuticals. We believe the […]
Monthly comment (Sep 2025): Signs of increased optimism
Summary September was dominated by US politics and rising investor appetite in the healthcare sector. The US government shut down after Democrats demanded an extension of health insurance marketplace subsidies in the budget negotiations. At the same time, an initial MFN agreement brought greater clarity on drug pricing and tariffs. The fund’s biotechnology segment performed […]